|Day Low/High||2.78 / 2.95|
|52 Wk Low/High||2.79 / 5.54|
Sadik Kassim, Ph.D., appointed Chief Scientific Officer and Knut Niss, Ph.D., named Chief Technology Officer
-- Expect to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Bunionectomy Surgery in 2Q18 --
Tamid enters exclusive licensing deal with UNC-Chapel Hill for three preclinical gene therapy product candidates
Research partner City of Hope to present initial Phase 1 data in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.